Three things happened in 72 hours that changed the GLP-1 market forever. On March 31, Novo Nordisk launched a $249/month Wegovy subscription program. On April 1, the FDA approved Foundayo (orforglipron). On April 2, Eli Lilly announced Foundayo would ship via LillyDirect starting April 6 at $149/month self-pay — with a $25/month savings card for commercially insured patients.
For the first time since GLP-1 medications entered the mainstream, prices are actually going down. Not because of government intervention or public outrage, but because two pharmaceutical giants are in an all-out war for your prescription. Here is what everything costs right now, what is coming next, and what you should do about it.
The Complete GLP-1 Pricing Table (April 2026)
Nobody else has this consolidated, so we built it. Every current GLP-1 option, what it actually costs, and how much weight you can expect to lose.
Foundayo (pill, insured) — $25/month via Lilly savings card — 12.4% average weight loss
Medicare Bridge Program (starts Jul 2026) — $50/month for Part D enrollees — varies by drug
Foundayo (pill, self-pay) — $149/month via LillyDirect, ships Apr 6 — 12.4% average weight loss
Compounded semaglutide — $100-299/month via telehealth providers — 15-17% average weight loss
Wegovy subscription — $249/month on 12-month plan via Ro, WW — 15-17% average weight loss
Wegovy HD injection (7.2mg) — TBD, hitting pharmacies April 2026 — 20.7% average weight loss
Zepbound injection — $1,060/month list price, insurance or self-pay — 20-22% average weight loss
Brand Ozempic — $998/month list price, insurance or NovoCare — 8-14% average weight loss
Read that list again. A year ago, the cheapest brand-name GLP-1 option was around $500/month with a savings card. Today it is $25. The floor has dropped out, and it is not done falling. For a full breakdown of every provider's current pricing, check our [cost tracker](/cost).
Novo Nordisk Is in Crisis Mode
Let us talk about what is really happening at Novo Nordisk, because it explains why prices are dropping so fast.
Novo's stock is down 43% from its 2025 peak. Their oral Wegovy launch in December was underwhelming — the fasting requirement turned off patients, and refill rates at 90 days came in at 78%, well below the 85% rate for the injectable. Then Foundayo got approved with zero dosing restrictions, and suddenly Novo's oral franchise looked vulnerable.
Their response has been frantic and telling. The $249/month Wegovy subscription launched literally the day before Foundayo's approval — a clear attempt to lock patients into 12-month commitments before they could consider switching. They are also pushing hard on the claim that Wegovy's 50mg oral pill beats orforglipron on weight loss in indirect comparisons, citing 15.1% versus 12.4%. That number is technically accurate but misleading — Foundayo's convenience advantage means real-world adherence will likely close that gap significantly. The pill you actually take every day beats the one you skip because you forgot to fast.
Novo also fast-tracked the rollout of Wegovy HD (the 7.2mg injectable dose), which showed 20.7% total body weight loss in trials. That is a genuinely impressive number and the highest of any single-agent GLP-1 on the market. If maximum weight loss is your goal and you do not mind injections, Wegovy HD is the new benchmark. But it is a defensive move — Novo is segmenting its own market, pushing needle-tolerant patients toward the premium injectable while fighting a price war on the oral side.
For a detailed head-to-head breakdown between the two leading drugs, see our [Ozempic vs. Wegovy comparison](/compare/ozempic-vs-wegovy).
The Compounding Crackdown Is Accelerating
Here is the other major force reshaping GLP-1 pricing: the FDA is squeezing compounded semaglutide out of the market.
In March alone, the FDA sent warning letters to 12 additional compounding pharmacies, bringing the total to over 40 since the crackdown began in late 2025. Several major telehealth platforms that built their entire business on compounded semaglutide have already pivoted to brand-name prescriptions. The writing is on the wall — compounded GLP-1 supply is shrinking, and it is not coming back.
But here is the thing: the price gap that made compounding attractive in the first place is closing fast. When brand-name Wegovy cost $1,350/month and compounded semaglutide was $150/month, the risk-reward calculus was obvious. Now? Foundayo is $149/month self-pay. The Wegovy subscription is $249/month. Compounded semaglutide at $100-299/month is no longer the obvious budget choice — it is a shrinking supply of an unregulated product that costs roughly the same as FDA-approved alternatives.
If you are currently on compounded semaglutide, we strongly recommend having a backup plan. Talk to your provider about transitioning to Foundayo or the Wegovy subscription before your compounder gets a warning letter or runs out of supply.
What You Should Do Right Now
Your best move depends entirely on your situation. Here is our honest take:
If you have commercial insurance — Foundayo at $25/month is unbeatable. Eli Lilly's savings card makes this the cheapest brand-name GLP-1 option by a wide margin. Yes, the weight loss is slightly lower than injectable options (12.4% vs. 15-20%), but at $25/month with zero dosing restrictions, the value proposition is extraordinary. Talk to your prescriber about switching or starting. For our full orforglipron deep dive, read the [Foundayo guide](/guides/orforglipron).
If you are uninsured or self-pay — Foundayo at $149/month through LillyDirect is the new baseline. It ships April 6. No insurance paperwork, no prior authorizations, no pharmacy games. Just order it. If you want the proven semaglutide track record instead, the Wegovy subscription at $249/month is solid but costs $100 more per month for a drug that requires fasting.
If you are 65 or older on Medicare — wait for July 1. The Medicare Bridge Program launches in 10 weeks and will cover Wegovy, Zepbound, and Foundayo at $50/month through Part D. Unless you have an urgent medical reason to start now, waiting three months will save you thousands over the course of treatment. Read our full [Medicare Bridge breakdown](/blog/medicare-glp1-bridge-what-to-know) for everything you need to prepare.
If you want maximum weight loss above all else — Wegovy HD is the new king at 20.7%. It is an injection, it will be expensive without insurance, and pricing details are still TBD. But if raw efficacy is your priority and you have coverage, nothing else comes close right now.
If you are on compounded semaglutide — start planning your exit. The FDA crackdown is real and accelerating. Compounded supply is shrinking month over month. With brand-name options now available at $149-249/month, the price advantage of compounding is nearly gone while the regulatory risk keeps growing.
The Bottom Line
April 2026 is a watershed moment for GLP-1 accessibility. For the first time, there are legitimate brand-name options under $150/month. Insurance copays are hitting $25. Medicare coverage starts in July at $50. And the competition between Eli Lilly and Novo Nordisk is only going to intensify from here.
The companies losing sleep are not just the compounders — it is the telehealth providers who built $300-500/month subscription models around brand-name injectables. When a patient can get Foundayo for $149 through LillyDirect or Wegovy for $249 through a subscription, the middleman markup becomes very hard to justify.
We will keep tracking every price change, every new program, and every FDA action as this price war plays out. Bookmark our [cost page](/cost) for real-time pricing updates, compare your options on our [best providers page](/best), and check back here for weekly coverage of the GLP-1 market.
The era of $1,000/month weight loss pills is ending. What comes next is going to be much more interesting.